At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
DFV890drug
Likely dose
DFV890 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
In Brief
A Phase 2 clinical trial evaluating DFV890 for Familial Cold Autoinflammatory Syndrome. Completed, enrolled 4 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Cold Autoinflammatory Syndrome
CountriesFrance, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartSep 2021
Primary CompletionDec 2022
Study CompletionMay 2023
TodayJul 2026
First PostedMay 3, 2021
Enrollment StartSep 20, 2021
Primary CompletionDec 13, 2022
Study CompletionMay 5, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
DFV890drug
100 mg of DFV890 film coated tablets twice daily (b.i.d.). for 3 days starting in the morning of Day 1 and 100 mg of DFV890 in the morning on the fourth day.